access

News

Coalition aims to improve cancer drug access in poorer natio...

Several of the top pharmaceutical companies have joined a new coalition that aims to improve access to cancer medicines in low- and lower-middle-income countries (LLMICs).

News

NICE backs Biogen's Vumerity for multiple sclerosis

Patients with relapsing-remitting multiple sclerosis (RRMS) in England, Wales and Northern Ireland can now access treatment with Biogen's oral therapy Vumerity, after NICE recommended the d

News

Drugmakers pledge shorter launch times for drugs in EU

Pharmaceutical companies have said they will try to carve months off the time between approval and launch for new medicines in Europe, and reduce disparities in access between countries.

News

NICE verdict on Trodelvy threatens unequal access to drug in...

In draft guidance, NICE has said it cannot recommend Gilead Sciences' Trodelvy in triple-negative breast cancer (TNBC), setting up a disparity in access to the drug via the NHS in the UK.

News

NHS grants fast-track access to Takeda's lung cancer drug Ex...

Takeda has secured UK approval for its lung cancer therapy Exkivity, with an NHS access deal that could see it prescribed to patients within the next few weeks.

News

Moderna squares off with US government over COVID jab patent

After being hailed as a triumph of public-private drug development, Moderna's partnership with the US government on its COVID-19 vaccine looks like it may descend into acrimony.

Coalition aims to improve cancer drug access in poorer natio...

NICE backs Biogen's Vumerity for multiple sclerosis

Drugmakers pledge shorter launch times for drugs in EU

NICE verdict on Trodelvy threatens unequal access to drug in...

NHS grants fast-track access to Takeda's lung cancer drug Ex...

Moderna squares off with US government over COVID jab patent

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

access

Editor's Picks